Opus Genetics, Inc. (IRD)
- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $4.05
- As of
Kresmion compiles this page from IRD's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
Opus Genetics, Inc. (IRD): no institutional manager tracked by Kresmion reported a non-option position in the latest Form 13F reporting quarter, and the most recent SEC filing on record for the company is a Form 10-Q filed 2026-11-10.
See the full IRD dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for IRD on one page. Preview it with sample data, then open it live with a free account.
Preview the IRD dossierActive events for IRD
- mediumEarnings below estimates
Q3-2026: Missed consensus by 205.9%, EPS $-0.46 vs $-0.1504 estimate
- high13F: funds added
3 tracked funds increased IRD this 2026Q2, institutional consensus
- high13F: large increase
CITADEL ADVISORS LLC added +479% to IRD (2026Q2)
- medium13F: new position
Point72 Asset Management, L.P. new position in IRD
- high13F: large increase
TWO SIGMA INVESTMENTS, LP added +134% to IRD (2026Q2)
FREE, NO ACCOUNT
Every event on IRD, as it fires
You are seeing 5 of 10 events recorded on IRD since 2026-05-30.
The five above landed across 3 days. The other 5 were recorded on 2 other days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
No non-option holdings from tracked managers in this reporting quarter. Other reporting quarters are linked above.
Recent SEC filings, IRD
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
More data on IRD
IRD against its peers
IRD's operating margin of -271.9% ranks in the 46th percentile of 13 Biotechnology sub-industry peers, fiscal periods ending between 2025-12-31 and 2026-06-30.
| Metric | IRD | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 14.2M USD | 44.6M USD | 32 | 13 |
| Operating margin | -271.9% | -212.9% | 46 | 13 |
| Net margin | -349.3% | -203.3% | 39 | 13 |
| Return on equity | -323.1% | -45.7% | 13 | 18 |
| 1 year | 117.2% | -23.2% | 98 | 20 |
Peers (21): CTNM, ALEC, MPLT, PEPG, CRMD, PBYI, CYDY, CCCC, SPRY, FENC, TECX, INDP, OCS, RZLT, PRTA, LYEL, AVTX, YDES, ASMB, CTMX, PHAT. Left out: ASPE (no annual filing), PRTCY (period gap), TRXB (no annual filing), BLSM (no annual filing). Fiscal periods ending between 2025-12-31 and 2026-06-30. Every figure is one full fiscal year read from one annual filing (IRD: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Cite this data
Kresmion counts the managers it follows that reported a non-option position in IRD on Form 13F-HR for the latest reporting quarter, orders those positions by the value each filing reports, and lists the company's latest SEC filings and the events Kresmion recorded on IRD in the last 180 days.
Upstream: SEC EDGAR filings for IRD
Kresmion, "Opus Genetics, Inc. (IRD) institutional holdings and SEC filings", data as of 2026-11-17, https://kresmion.com/research/IRD. Upstream data: SEC EDGAR filings for IRD.
Link to this data (HTML):
<a href="https://kresmion.com/research/IRD">Opus Genetics, Inc. (IRD) institutional holdings and SEC filings (Kresmion)</a>
Writing about this? Press contact and ready-to-quote figures
Follow IRD on a live board
Kresmion is a source-first market terminal for cross-asset market intelligence. Open a board scoped to IRD for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.